Patents by Inventor S. George Kottayil
S. George Kottayil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11857520Abstract: A nasal spray formulation and a method of using a locally acting sodium channel blocker to treat pain is disclosed, wherein the nasal spray formulation comprises from about 5% to about 30% w/v of a locally active sodium channel blocker, from about 0.25% to about 5% w/v of a buffering agent, and from about 5 to about 99% w/v of a pharmaceutically acceptable carrier for nasal administration. The nasal spray formulation is preferably contained in a mechanical multi-dose pump which sprays a unit dose of the nasal spray formulation with a wide plume and small droplet size, such that the unit dose is administered by actuating the mechanical multi-dose spray pump device and spraying a volume of the nasal spray formulation into each nostril of a human subject. Preferably, the nasal spray formulation does not include a preservative.Type: GrantFiled: December 4, 2019Date of Patent: January 2, 2024Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru, Kamalkishore Pati
-
Publication number: 20230364068Abstract: A method of providing an IV nimodipine infusion regimen using a solubilized nimodipine solution suitable for IV administration is disclosed. The IV nimodipine infusion regimen provides a constant infusion rate over the (entire) 24 hour period supplemented with higher infusions of nimodipine at set intervals to duplicate the 24 hour AUC and Cmax of an oral nimodipine dose.Type: ApplicationFiled: May 10, 2023Publication date: November 16, 2023Applicant: ACASTI PHARMA U.S., INC.Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Kamalkishore Pati, Vimal Kavuru
-
Patent number: 11433062Abstract: A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution, an organic solvent, an oil, or a cyclodextrin, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80.Type: GrantFiled: September 3, 2020Date of Patent: September 6, 2022Assignee: Acasti Pharma U.S., Inc.Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru
-
Publication number: 20220133642Abstract: A polymeric bio-adhesive film forming topical spray formulation providing a modified, pulsatile (e.g., biphasic) release of the active agent(s) once the solvent evaporates and the film sets, e.g., on human skin is disclosed. In certain embodiments, the active agent is bupivacaine hydrochloride.Type: ApplicationFiled: December 17, 2021Publication date: May 5, 2022Applicant: GRACE THERAPEUTICS INC.Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru
-
Publication number: 20220133641Abstract: A polymeric bio-adhesive film forming topical spray formulation providing a modified, pulsatile (e.g., biphasic) release of the active agent(s) once the solvent evaporates and the film sets, e.g., on human skin is disclosed. In certain embodiments, the active agent is bupivacaine hydrochloride.Type: ApplicationFiled: December 17, 2021Publication date: May 5, 2022Applicant: GRACE THERAPEUTICS INC.Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru
-
Patent number: 11291672Abstract: A stable oral spray formulation comprising a glucocorticoid together with other excipients is disclosed. In preferred embodiments, the spray formulation is used to treat neurological disorders such as ataxia by being sprayed in an effective dose into the mouth of a patient.Type: GrantFiled: January 12, 2017Date of Patent: April 5, 2022Assignee: GRACE THERAPEUTICS INC.Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru
-
Publication number: 20220062256Abstract: A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution substantially free of organic solvent, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80.Type: ApplicationFiled: November 10, 2021Publication date: March 3, 2022Applicant: GRACE THERAPEUTICS INC.Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru, Kamalkishore Pati
-
Publication number: 20200397769Abstract: A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution, an organic solvent, an oil, or a cyclodextrin, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80.Type: ApplicationFiled: September 8, 2020Publication date: December 24, 2020Applicant: NORTIC HOLDINGS INC.Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru, Kamalkishore Pati
-
Publication number: 20200397773Abstract: A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution, an organic solvent, an oil, or a cyclodextrin, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80.Type: ApplicationFiled: September 3, 2020Publication date: December 24, 2020Applicant: NORTIC HOLDINGS INC.Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru
-
Patent number: 10799486Abstract: A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution, an organic solvent, an oil, or a cyclodextrin, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80.Type: GrantFiled: July 26, 2018Date of Patent: October 13, 2020Assignee: NORTIC HOLDINGS INC.Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru, Kamalkishore Pati
-
Patent number: 10765671Abstract: A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution, an organic solvent, an oil, or a cyclodextrin, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80.Type: GrantFiled: July 26, 2018Date of Patent: September 8, 2020Assignee: NORTIC HOLDINGS INC.Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru
-
Publication number: 20200197338Abstract: A nasal spray formulation and a method of using a locally acting sodium channel blocker to treat pain is disclosed, wherein the nasal spray formulation comprises from about 5% to about 30% w/v of a locally active sodium channel blocker, from about 0.25% to about 5% w/v of a buffering agent, and from about 5 to about 99% w/v of a pharmaceutically acceptable carrier for nasal administration. The nasal spray formulation is preferably contained in a mechanical multi-dose pump which sprays a unit dose of the nasal spray formulation with a wide plume and small droplet size, such that the unit dose is administered by actuating the mechanical multi-dose spray pump device and spraying a volume of the nasal spray formulation into each nostril of a human subject. Preferably, the nasal spray formulation does not include a preservative.Type: ApplicationFiled: December 4, 2019Publication date: June 25, 2020Applicant: Nortic Holdings Inc.Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru, Kamalkishore Pati
-
Publication number: 20200163947Abstract: A method of treating a human patient suffering from subarachnoid hemorrhage (SAH), intra-cerebral hemorrhage, and traumatic brain injuries (TBI), and the like, comprising administering a nimodipine formulation suitable for parenteral injection, e.g., either via the subcutaneous or intramuscular route, is disclosed.Type: ApplicationFiled: October 31, 2019Publication date: May 28, 2020Applicant: Nortic Holdings Inc.Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru, Kamalkishore Pati
-
Patent number: 10610523Abstract: The present invention is directed to sublingual formulations containing fentanyl, a pharmaceutically acceptable sale thereof, or derivative thereof, suitable for administration to a patient, and methods for treatment with the formulations.Type: GrantFiled: April 4, 2017Date of Patent: April 7, 2020Assignee: BTCP PHARMA, LLCInventors: S. George Kottayil, Venkat R. Goskonda, Zhongyuan Zhu, Linet Kattookaran, Neha Parikh
-
Patent number: 10406122Abstract: A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously over a prolonged time period is disclosed. In certain embodiments, the dose is intravenously administered in a time period from about 10 minutes to about 3 hours, preferably from about 10 minutes to about 30 minutes. In other embodiments, intravenous doses are administered at suitable time intervals over a time period from about 3 hours to 48 hours.Type: GrantFiled: May 7, 2018Date of Patent: September 10, 2019Assignee: Revogenex Ireland Ltd.Inventors: S. George Kottayil, Jeffrey H. Ping
-
Publication number: 20190255033Abstract: A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution substantially free of organic solvent, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80.Type: ApplicationFiled: February 21, 2019Publication date: August 22, 2019Applicant: NORTIC HOLDINGS INC.Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru, Kamalkishore Pati
-
Publication number: 20180325886Abstract: A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution, an organic solvent, an oil, or a cyclodextrin, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80.Type: ApplicationFiled: July 26, 2018Publication date: November 15, 2018Applicant: NORTIC HOLDINGS INC.Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru
-
Publication number: 20180325882Abstract: A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution, an organic solvent, an oil, or a cyclodextrin, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80.Type: ApplicationFiled: July 26, 2018Publication date: November 15, 2018Applicant: NORTIC HOLDINGS INC.Inventors: S. George Kottayil, Amresh Kumar, Prasanna Sunthankar, Vimal Kavuru, Kamalkishore Pati
-
Publication number: 20180303771Abstract: A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously over a prolonged time period is disclosed. In certain embodiments, the dose is intravenously administered in a time period from about 10 minutes to about 3 hours, preferably from about 10 minutes to about 30 minutes. In other embodiments, intravenous doses are administered at suitable time intervals over a time period from about 3 hours to 48 hours.Type: ApplicationFiled: May 7, 2018Publication date: October 25, 2018Inventors: S. George KOTTAYIL, Jeffrey H. PING
-
Publication number: 20180303813Abstract: The present invention is directed to sublingual formulations containing fentanyl, a pharmaceutically acceptable salt thereof, or derivative thereof, suitable for administration to a patient, and methods for treatment with the formulations.Type: ApplicationFiled: June 27, 2018Publication date: October 25, 2018Inventors: S. George Kottayil, Venkat R. Goskonda, Zhongyuan Zhu, Linet Kattookaran, Neha Parikh